10/22/2014

Composition of the Nomination Committee of Orion Corporation

ORION CORPORATION      STOCK EXCHANGE RELEASE 22 OCTOBER  2014 at 6.25 p.m. EEST              

Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:  

Kari Jussi Aho
Matti Kavetvuo
Timo Ritakallio
Seppo Salonen
Hannu Syrjänen
Jukka Ylppö


Matti Kavetvuo was elected Chairman of the Committee.

The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.

The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at
http://www.orion.fi/en/Orion-group/corporate-governance/board-of-directors/board-committees/, a page in the Corporate Governance section of the Orion Group internet website.

  
Orion Corporation

 

Timo Lappalainen
President and CEO
 

 
 

Olli Huotari
SVP, Corporate Functions
 

                                                                       
Contact person:
Timo Lappalainen
tel. +358 10 426 3692

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.